Application Advances on Novel Techniques in Multi-target Drugs Discovery

Abstract

Abstract: Compared with drugs designed to act against individual molecular targets，multi-target drugs that impact multiple targets simultaneously are better at controlling complex disease systems and are less prone to drug resistance. However，how to design multi-target drugs presents a great challenge. With the rapid progress in multi-target drugs research，some novel techniques in laboratories have emerged and are very likely to be effectively applied in combating multigenic diseases or diseases that affect multiple tissues. This review deals with the recent progress in multi-target drugs research，some novel techniques and their applications in drug discovery.

Key words: multi-target drugs, multi-target anti-miRNA antisense oligonucleotides technology, surface plasmon resonance technology, multidimensional liquid chromatography/mass spectrometry

CLC Number:

R91
R9-39

LIU Shao-qiang，TIE Lu，LI Xue-jun. Application Advances on Novel Techniques in Multi-target Drugs Discovery[J]. Acta Neuropharmacologica, 2011, 1(4): 48-54.

References

1 Grant R Zimmermann, Joseph Lehar, Curtis T Keith. Multi-target therapeutics: when the whole is greater than the sum of the parts[J]. Drug Discov Today, 2007, 12(1-2):34-42.

2 Peter Csermely, Vilmos Agoston, Sandor Pongor. The efficiency of multi-target drugs: the network approach might help drug design[J]. Trends Pharmacol Sci, 2005, 26(4):178-182.

3 Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases[J]. Expert Rev Clin Pharmacol,2011, 4(3):293-298.

4 Bajda M, Guzior N, Ignasik M, et al. Multi-target-directed ligands in Alzheimer's disease treatment[J]. Curr Med Chem, 2011, 18(32):4949-4975.

5 Min-Hee Pang, Yuntae Kim, Kyung Woon Jung, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs[J]. Drug Discov Today, 2012,17(9-10):425-434.

6 Ohlson S. Designing transient binding drugs: a new concept for drug discovery[J]. Drug Discov Today, 2008, 13(9-10):433-439.

7 Richard Morphy, Corinne Kay, Zoran Rankovic. From magic bullets to designed multiple ligands[J]. Drug Discovery Today, 2004, 9(15):641-651.

8 Louis M Tsai, Di Yu. MicroRNAs in common diseases and potential therapeutic applications[J]. Clin Exp Pharmacol Physiol, 2010, 37(1):102-107.

9 Ranjan J Perera, Animesh Ray. MicroRNAs in the search for understanding human diseases[J]. Bio drugs, 2007, 21(2):97-104.

10 Boutla A, Delidakis C, Tabler M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identi?cation of putative target genes[J]. Nucleic Acids Res, 2003, 31(17):4973-4980.

11 Gayathri R Devi, Tomasz M Beer, Christopher L Corless, et al. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors[J]. Clin Cancer Res, 2005, 11(10):3930-3938.

12 Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides[J]. Gene Ther, 2011, 18(12):1111-1120.

13 Lu Y, Xiao J, Lin H, et al. Complex antisense inhibitors offer a superior approach for microRNA research and therapy[J]. Nucleic Acids Res, 2009, 37:e24-e33.

14 Thomas Thum, Paolo Galuppo, Christian Wolf, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure[J]. Circulation, 2007, 116(3):258-267.

15 Stefano Volinia, George A Calin, Liu Changgong, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci U S A, 2006, 103(7):2257-2261.

16 Meng Qingwen, Zhang Zaiping, Wang Wen, et al. Enhanced inhibition of Avian leukosis virus subgroup J replication by multi-target miRNAs[J]. Virol J, 2011, 8(1):556.

17 Pranavan Thillaivinayagalingam, Julien Gommeaux, Michael McLoughlin, et al. Biopharmaceutical production: Applications of surface plasmon resonance biosensors[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2010, 878(2):149-153.

18 Visser NF, Heck AJ. Surface plasmon resonance mass spectrometry in proteomics[J]. Expert Rev Proteomics, 2008, 5(3):425-433.

19 Jacquemart R, Chavane N, Durocher Y, et al. At-line monitoring of bioreactor protein production by Surface Plasmon Resonance[J]. Biotechnol Bioeng, 2008, 100(1):184-188.

20 Bader B, Kuhn K, Owen DJ, et al. Bioorganic synthesis of lipid-modified proteins for the study of signal transduction[J]. Nature, 2000, 403(6766):223-226.

21 Anthony M Giannetti, Bruce D Koch, Michelle F Browner. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors[J]. J Med Chem, 2008, 51(3):574-580.

22 Navratilova I, Hopkins AL. Emerging role of surface plasmon resonance in fragment-based drug discovery[J]. Future Med Chem, 2011, 3(14):1809-1820.

23 Heim-Riether A, Taylor SJ, Liang S, et al. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors[J]. Bioorg Med Chem Lett, 2009, 19(18):5321-5324.

24 Neumann T, Junker HD, Schmidt K, et al. SPR-based fragment screening: advantages and applications[J]. Curr Top Med Chem, 2007, 7(16):1630-1642.

25 Stephen S Antonysamy, Brandon Aubol, Jeff Blaney, et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors[J]. Bioorg Med Chem Lett, 2008, 18(9):2990-2995.

26 Baty JW, Hampton MB, Winterbourn CC. Detection of oxidant sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis[J]. Proteomics, 2002, 2(9):1261-1266.

27 Wang Hong, Hanash S. Multi-dimensional liquid phase based separations in proteomics[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 787(1):11-18.

28 Bilello JA. The agony and ecstasy of "OMIC" technologies in drug development[J]. Current Mol Med, 2005, 5(1):39-52.

29 Zhang Xiang, Fang Aiqin, Catherine P Riley, et al. Multi-dimensional liquid chromatography in proteomics-A review[J]. Anal Chim Acta, 2010, 664(2):101-113.

30 Scott W Simpkins, Jeremy W Bedard, Stephen R Groskreutz, et al. Targeted three-dimensional liquid chromatography: a versatile tool for quantitative trace analysis in complex matrices[J]. J Chromatogr A, 2010, 1217(49):7648-7660.

31 Gao M, Qi D, Zhang P, et al. Development of multidimensional liquid chromatography and application in proteomic analysis[J]. Expert Rev Proteomics, 2010, 7(5):665-678.

32 Baynham MT, Patel S, Moaddel R, et al. Multidimensional on-line screening for ligands to the alpha3beta4 neuronal nicotinic acetylcholine receptor using an immobilized nicotinic receptor liquid chromatographic stationary phase[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 772(1):155-161.

33 Dai Jie, Jin Wenhai, Sheng Quanhu, et al. Protein phosphorylation and expression profiling by Yin-Yang multidimensional liquid chromatography (Yin-Yang MDLC) mass spectrometry[J]. J Proteome Res, 2007, 6(1):250-262.

34 Hao P, Qian J, Dutta B, et al. Enhanced Separation and Characterization of Deamidated Peptides with RP-ERLIC-Based Multidimensional Chromatography Coupled with Tandem Mass Spectrometry[J]. J Proteome Res, 2012,11(3):1804-1811.

35 Martin Vollmer, Edgar Nägele, Patric Hörth. Differential Proteome Analysis: Two-Dimensional Nano-LC/MS of E.Coli Proteome Grown on Different Carbon Sources[J]. J Biomol Tech, 2003, 14(2):128-135.

36 Jae Hong Kim, Ji Hyun Yeom, Jeong Jae Ko, et al. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles[J]. J Biotechnol, 2011, 155(3):287-292.

37 Yoshida M, Loo JA, Lepley RA. Proteomics as a tool in the pharmaceutical drug design process[J]. Curr Pharm Des, 2001, 7(4):291-310.